A142 INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRE AN INCREASED ADALIMUMAB DRUG LEVEL TO SIMULTANEOUSLY ACHIEVE CLINICAL AND BIOLOGICAL REMISSION

BACKGROUND: Physicians use therapeutic drug monitoring of adalimumab (ADA) as an optimization tool to guide patient therapy with inflammatory bowel disease (IBD). IBD consists primarily of Crohn’s disease (CD) and ulcerative colitis (UC). Presently, the literature on ADA therapeutic boundaries recom...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Can Assoc Gastroenterol
Autori principali: Cookson, T A, Stern, N C, Sutton, R T, Fedorak, R, Halloran, B, Dieleman, L A, Wong, K, Huang, V, Peerani, F, van Zanten, S, Lazarescu, A, Kroeker, K
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2019
Soggetti:
Posters Of Distinction
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512604/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.141
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi